Stryker Sells U.S. Spinal Implants Business

Stryker to Sell its U.S. Spinal Implants Business
“We believe that the spinal implants business, with its comprehensive portfolio and strong sales channel, will thrive as an independent company," said Kevin A. Lobo, Chair and Chief Executive Officer, Stryker. "With dedicated resources and a focused strategy, the business will be well positioned to succeed as part of Viscogliosi Brothers.”
Stryker to sell spine business: 8 notes for ASCs
Here are eight things for ASCs to know about the sale: 1. Stryker's U.S. spine segment will be sold to investment firm Viscogliosi Brothers. 2. That group will create VB Spine, which will be a strategic partner to Stryker with exclusive access to the company's Mako Spine and Copilot technology.
Stryker to Sell Spinal Implants Business to Viscogliosi Brothers
Stryker has agreed to sell its U.S. spinal implants business to Viscogliosi Brothers to create a newly formed company called VB Spine. The medical technology company said Tuesday the New York City-based Viscogliosi Brothers specializes in neuro-musculoskeletal treatments.
Stryker announces definitive agreement for the sale of its U.S. spinal implants business and plans to sell related international business
Stryker (NYSE:SYK), a global leader in medical technologies, announced today a definitive agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, LLC, a family-owned investment firm specializing in the neuro-musculoskeletal space,
Stryker to sell spinal implants business
Stryker reported goodwill and other impairments of $818 million related to the spine business in the fourth quarter.
Hosted on MSN2h
Stryker price target raised to $427 from $384 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Stryker (SYK) to $427 from $384 and keeps a Neutral rating on the shares ...
Stryker Corp. stock underperforms Wednesday when compared to competitors
Shares of Stryker Corp. SYK slid 1.03% to $391.07 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.47% to 6,039.31 and Dow ...
Stryker’s Strategic Moves and Strong Performance Drive Buy Rating
In a report released today, Michael Matson from Needham reiterated a Buy rating on Stryker (SYK – Research Report), with a price target of ...
Stryker's SWOT analysis: medical tech giant's stock poised for growth
Stryker Corporation (NYSE:SYK), a leading player in the medical technology industry with a substantial market capitalization of $149 billion, has been making waves with its strong financial ...
bovnews12h
Stock Shock: The Unpredictable Rise and Fall of SYK—What’s Driving the Drama?
On Tuesday, Stryker Corp (SYK) stock saw a decline, ending the day at $395.15 which represents a decrease of $-4.75 or -1.19% from the prior close of $399.9. The stock opened at $400.61 and touched a ...
Buy Rating for Stryker: Robust Performance and Strategic Growth Drivers
Analyst Patrick Wood from Morgan Stanley maintained a Buy rating on Stryker (SYK – Research Report) and keeping the price target at ...
Becker's Spine Review9h
Stryker's shoulder robot earns FDA approval
Stryker's Mako shoulder robot earned FDA approval in December, Jason Beach, vice president of finance and investor relations, said in a Jan. 28 earnings call.
A Glimpse Into The Expert Outlook On Stryker Through 14 Analysts
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...